⌘K
t
Vulcan Two Group plc announced it will release its Full Year Results on Thursday 21 May 2026. Following this, the management team, including CEO Michael Kraftman, CFO Keith Butcher, and COO Brendan O'Brien, will host a live investor presentation at 12:30pm (BST) on the same day via the Investor Meet Company platform.
| Date | 18 May 2026 |
| Time | 07:00:09 |
| Category | Results |
| ID | 6137E |
18 May 2026
Vulcan Two Group plc
(the "Company", "Group" or "Vulcan Two")
Notice of Results and Investor Presentation
Following the release of the Company's Full Year Results on Thursday 21 May 2026, the management team of Vulcan Two Group plc, the company aiming to create the UK's leading regulated ePharmacy through buy-and-build, will be hosting a live presentation at 12:30pm (BST) via the Investor Meet Company platform.
Michael Kraftman (CEO), Keith Butcher (CFO) and Brendan O'Brien (COO) will present an overview of the Company's vision, its proven buy-and-build strategy, and the significant growth opportunity within the UK ePharmacy market.
The presentation is open to all existing and potential shareholders and registration can be completed via the following link: www.investormeetcompany.com/vulcan-two-group-plc/register-investor
Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.
For further information please contact:
|
Vulcan Two Group plc Michael Kraftman, Chief Executive Officer Keith Butcher, Chief Finance Officer Brendan O'Brien, Chief Operating Officer |
Email: [email protected] |
|
Canaccord Genuity Limited Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott |
Tel: +44 (0) 20 7523 8000 |
|
Alma Strategic Communications Justine James / Sam Modlin / Will Merison |
Email: [email protected] Tel: +44 (0) 20 3405 0205 |
Notes to Editors
Vulcan Two Group plc (AIM:VUL) is creating the UK's leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.
The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise.
For more information, visit www.vulcantwo.com